MedCity News

MedCityNews is a top online platform that covers the business side of healthcare innovation. We provide valuable insights into upcoming trends and important topics through a combination of breaking news and in-depth analysis. Our content focuses on both emerging startups and well-known industry figures, as well as key policies and significant deals in the healthcare sector.

National

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#423324

United States

#150219

Health/Health

#2943

Traffic sources

Monthly visitors

Articles

Navigating the AI in Healthcare Landscape and Its Future: A Preview of INVEST Digital Health 2025

3 days ago | medcitynews.com | Stephanie Baum

The rise of artificial intelligence and the increasingly diverse applications for AI in healthcare generates excitement for its potential. But it should also give us pause for the potential consequences of widespread adoption. MedCity INVEST Digital Health (Opens in a new window)on September 18 at Pegasus Park in Dallas will explore this theme through a series of discussions leading up to our annual Pitch Perfect contest, where startups pitch their companies to a team of investor judges.
Kura Oncology Drug’s Data at ASCO Support FDA Filing Now Under Priority Review for Leukemia

3 days ago | medcitynews.com | Frank Vinluan

A Kura Oncology and Kyowa Kirin-partnered drug vying to become the first FDA-approved treatment for cases of acute myeloid leukemia (AML) carrying a particular genetic signature will have its regulatory review supported by clinical data showing the therapy achieved statistically significant improvement in signs and symptoms of the disease.
BMS Buys Into BioNTech Bispecific Antibody, Putting Up $1.5B to Collaborate in Multiple Cancers

4 days ago | medcitynews.com | Frank Vinluan

BioNTech’s oncology strategy centers on a bispecific antibody that the company envisions as the backbone of many potential drug combinations for many types of cancer. Bristol Myer Squibb is buying into that strategy, paying $1.5 billion up front to partner on the clinical-stage asset, which could have applications as part of combinations with the pharmaceutical giant’s own immunotherapies and other cancer drugs.
At ASCO, Merck KGaA Shows How Its Drug Measures Up as Treatment for Rare Type of Tumor

5 days ago | medcitynews.com | Frank Vinluan

Patients with tenosynovial giant cell tumor can take some comfort in knowing that this rare type of tumor affecting joints won’t kill them. But that doesn’t make living with the disease easy. Merck KGaA has data from a pivotal study showing its once daily pill helped, leading to reduction in pain and improvement in physical movement. Regulatory submissions are now planned. But first, data from the drug’s pivotal study will be shared at the largest cancer conference in the world.
Analysis: The No Good, Very Bad Year for UnitedHealth

6 days ago | medcitynews.com | Marissa Plescia

It goes without saying that this past year has been anything but easy for UnitedHealth Group. As one of the biggest healthcare companies in the U.S., it has long been a reliable stock to invest in. But in the last few months, its stock has dropped nearly 50%,it has switched CEOs and seems to be on the backfoot — a surprising development for one of the biggest names in healthcare. How did all this unfold and more importantly, can it dig out of it?
Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug

1 week ago | medcitynews.com | Frank Vinluan

Astellas Pharma already has the first FDA approval for a therapy that goes after Claudin 18.2, a protein whose overexpression on the surface of cells in gastrointestinal cancers makes it an attractive drug target. But the company has shown interest in pursuing multiple ways to drug this target, and it’s furthering this strategy with a deal that secures rights to a clinical-stage molecule from Evopoint Biosciences. Astellas’s approved drug, Vyloy, is a monoclonal antibody.
4 Notable Health Tech Funding Announcements in May

1 week ago | medcitynews.com | Marissa Plescia

This roundup is meant to highlight some of the most notable funding rounds of the month and is not intended to be comprehensive. Health tech companies made several major funding announcements in May. Here is a list of some of the biggest funding rounds. Cohere Health raises $90 million in Series C fundingBoston-based Cohere Health provides AI-powered prior authorization solutions to help improve the relationship between payers and providers.
MedCity FemFwd: Investment Trends In Women's Health

1 week ago | medcitynews.com | Marissa Plescia

Welcome back to another episode of MedCity FemFwd, a podcast dedicated to discussing the breakthroughs and challenges in women’s health. In this episode, we’re joined by Margaret Malone, principal of Flare Capital Partners. We discuss the investment trends she’s following in the women’s health space and advice she has for startups. Below is the transcript. Marissa Plescia: Welcome back to another episode of MedCity FemFwd. I’m Marissa Plescia, reporter for MedCity News.
Precision Pfizer Drug Leads to ‘Unprecedented’ Survival in Colorectal Cancer, Data at ASCO Show

1 week ago | medcitynews.com | Frank Vinluan

A precision oncology Pfizer drug now has clinical data showing it helped patients with colorectal cancer live longer, results that study investigators say could change the way physicians treat those whose disease exhibits the specific genetic signature targeted by this therapy. Patients who received the Pfizer drug Braftovi alongside standard of care colorectal cancer therapies had a 51% lower risk of dying than patients treated with the standard of care chemotherapy.
Priority Health Teams Up with Virta Health for Diabetes, Weight Loss Support

1 week ago | medcitynews.com | Marissa Plescia

Priority Health, a nonprofit health plan with 1.3 million members, announced a partnership with Virta Health on Tuesday to offer employers support for weight management and diabetes. Denver, Colorado-based Virta Health is a digital health company that works with payers and employers and offers nutrition support and medication prescribing if necessary. It creates personalized care plans based on the patient’s medical history, personal goals and risk factors.